The treatment of retinoblastoma cells with 5-Aza-CdR caused the demethylation of the MEG3 promoter, resulting in the upregulation of MEG3 and further inactivation of the Wnt/β-catenin pathway, leading to the inhibition of cell growth [35]. The gene discussed is MEG3; the disease is retinoblastoma.